Hepatocellular carcinoma epidemiology and demographics: Difference between revisions
| Line 10: | Line 10: | ||
The [[epidemiology]] of hepatocellular carcinoma exhibits two main patterns, one in North America and Western Europe and the other in non-Western countries, such as those in Sub-Saharan Africa, Central Asia and Southeast Asia, and the Amazon basin. Although the [[incidence]] of hepatocellular carcinoma is increasing worldwide due to its association with [[viral]] [[infections]]; it still remains relatively uncommon in the United States and Western Europe. HCC is the fastest growing cause of [[cancer]] related deaths and the second most common cause of [[mortality]] among women.<ref name="pmid29333065">{{cite journal |vauthors=Papadopoulos N, Argiana V, Deutsch M |title=Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management |journal=Ann Gastroenterol |volume=31 |issue=1 |pages=35–41 |year=2018 |pmid=29333065 |doi=10.20524/aog.2017.0204 |url=}}</ref><ref name="Didi-Kouko CoulibalyYeboua2017">{{cite journal|last1=Didi-Kouko Coulibaly|first1=Judith|last2=Yeboua|first2=Mireille|last3=Kouassi Mbengue|first3=Alphonsine|last4=Kouadio|first4=Emile Allah|last5=Anzouan-Kacou Kissi|first5=Henriette|last6=Binan|first6=Allah Yves-Omer|last7=Lohoues Kouacou|first7=Marie-Jeanne|last8=Attia|first8=Alain|last9=N’Drin|first9=Dominique Yao|last10=Toutou|first10=Toussaint|last11=Adoubi|first11=Innocent|last12=Pineau|first12=Pascal|title=Evolution of hepatocellular carcinoma epidemiology in Côte d’Ivoire|journal=Bulletin du Cancer|volume=104|issue=11|year=2017|pages=937–945|issn=00074551|doi=10.1016/j.bulcan.2017.09.010}}</ref><ref name="WHO">{{cite web | last = | first = | authorlink = | coauthors = | title =Cancer | work = | publisher =World Health Organization | date =February 2006 | url =http://www.who.int/mediacentre/factsheets/fs297/en/ | format = | doi = | accessdate =2007-05-24 }}</ref><ref name="pmid28987047">{{cite journal |vauthors=Budny A, Kozłowski P, Kamińska M, Jankiewicz M, Kolak A, Budny B, Budny W, Niemunis-Sawicka J, Szczypiór G, Kurniawka B, Burdan F |title=[Epidemiology and risk factors of hepatocellular carcinoma] |language=Polish |journal=Pol. Merkur. Lekarski |volume=43 |issue=255 |pages=133–139 |year=2017 |pmid=28987047 |doi= |url=}}</ref> | The [[epidemiology]] of hepatocellular carcinoma exhibits two main patterns, one in North America and Western Europe and the other in non-Western countries, such as those in Sub-Saharan Africa, Central Asia and Southeast Asia, and the Amazon basin. Although the [[incidence]] of hepatocellular carcinoma is increasing worldwide due to its association with [[viral]] [[infections]]; it still remains relatively uncommon in the United States and Western Europe. HCC is the fastest growing cause of [[cancer]] related deaths and the second most common cause of [[mortality]] among women.<ref name="pmid29333065">{{cite journal |vauthors=Papadopoulos N, Argiana V, Deutsch M |title=Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management |journal=Ann Gastroenterol |volume=31 |issue=1 |pages=35–41 |year=2018 |pmid=29333065 |doi=10.20524/aog.2017.0204 |url=}}</ref><ref name="Didi-Kouko CoulibalyYeboua2017">{{cite journal|last1=Didi-Kouko Coulibaly|first1=Judith|last2=Yeboua|first2=Mireille|last3=Kouassi Mbengue|first3=Alphonsine|last4=Kouadio|first4=Emile Allah|last5=Anzouan-Kacou Kissi|first5=Henriette|last6=Binan|first6=Allah Yves-Omer|last7=Lohoues Kouacou|first7=Marie-Jeanne|last8=Attia|first8=Alain|last9=N’Drin|first9=Dominique Yao|last10=Toutou|first10=Toussaint|last11=Adoubi|first11=Innocent|last12=Pineau|first12=Pascal|title=Evolution of hepatocellular carcinoma epidemiology in Côte d’Ivoire|journal=Bulletin du Cancer|volume=104|issue=11|year=2017|pages=937–945|issn=00074551|doi=10.1016/j.bulcan.2017.09.010}}</ref><ref name="WHO">{{cite web | last = | first = | authorlink = | coauthors = | title =Cancer | work = | publisher =World Health Organization | date =February 2006 | url =http://www.who.int/mediacentre/factsheets/fs297/en/ | format = | doi = | accessdate =2007-05-24 }}</ref><ref name="pmid28987047">{{cite journal |vauthors=Budny A, Kozłowski P, Kamińska M, Jankiewicz M, Kolak A, Budny B, Budny W, Niemunis-Sawicka J, Szczypiór G, Kurniawka B, Burdan F |title=[Epidemiology and risk factors of hepatocellular carcinoma] |language=Polish |journal=Pol. Merkur. Lekarski |volume=43 |issue=255 |pages=133–139 |year=2017 |pmid=28987047 |doi= |url=}}</ref> | ||
===Incidence=== | ===Incidence=== | ||
*The incidence/ | In almost 90% of the cases Hepatocellular carcinoma patients have underlying liver cirrhosis.<ref name="Colombode Franchis1991">{{cite journal|last1=Colombo|first1=Massimo|last2=de Franchis|first2=Roberto|last3=Del Ninno|first3=Ersilio|last4=Sangiovanni|first4=Angelo|last5=De Fazio|first5=Cristina|last6=Tommasini|first6=Maurizio|last7=Donato|first7=M. Francesca|last8=Piva|first8=Anna|last9=Di Carlo|first9=Valerio|last10=Dioguardi|first10=Nicola|title=Hepatocellular Carcinoma in Italian Patients with Cirrhosis|journal=New England Journal of Medicine|volume=325|issue=10|year=1991|pages=675–680|issn=0028-4793|doi=10.1056/NEJM199109053251002}}</ref> | ||
*In | *The incidence of Hepatocellular carcinoma is described below:<ref name="pmid23632345">{{cite journal |vauthors=Mittal S, El-Serag HB |title=Epidemiology of hepatocellular carcinoma: consider the population |journal=J. Clin. Gastroenterol. |volume=47 Suppl |issue= |pages=S2–6 |year=2013 |pmid=23632345 |pmc=3683119 |doi=10.1097/MCG.0b013e3182872f29 |url=}}</ref><ref name="pmid17923599">{{cite journal |vauthors=El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J |title=Epidemiology of hepatocellular carcinoma in Hispanics in the United States |journal=Arch. Intern. Med. |volume=167 |issue=18 |pages=1983–9 |year=2007 |pmid=17923599 |doi=10.1001/archinte.167.18.1983 |url=}}</ref><ref name="Colombode Franchis1991">{{cite journal|last1=Colombo|first1=Massimo|last2=de Franchis|first2=Roberto|last3=Del Ninno|first3=Ersilio|last4=Sangiovanni|first4=Angelo|last5=De Fazio|first5=Cristina|last6=Tommasini|first6=Maurizio|last7=Donato|first7=M. Francesca|last8=Piva|first8=Anna|last9=Di Carlo|first9=Valerio|last10=Dioguardi|first10=Nicola|title=Hepatocellular Carcinoma in Italian Patients with Cirrhosis|journal=New England Journal of Medicine|volume=325|issue=10|year=1991|pages=675–680|issn=0028-4793|doi=10.1056/NEJM199109053251002}}</ref> | ||
*In 1975-77, the incidence of Hepatocellular carcinoma in the United states was 1.4 per 100,000 which increased to 4.8 per 100,000 in 2005-2007.<ref>Davila JA, El-Serag HB. The Rising Incidence of Hepatocellular Carcinoma in the United States: an Update. Gastroenterology. 2012;142(suppl 1):S914–S914.</ref> | |||
*In 2007, the incidence of Hepatocellular carcinoma was estimated to be over 20 cases per 100,000 persons in sub-Saharaa, Africa and Eastern Asia. | |||
*In 2007, the incidence of Hepatocellular carcinoma was estimated to be 10-20 per 100,000 persons in Mediterranean countries such as Italy, Spain, and Greece. | |||
*In 2007, the incidence of Hepatocellular carcinoma was estimated to be <5 per 100,000 persons in North and South America. | |||
===Prevalence=== | ===Prevalence=== | ||
Revision as of 21:36, 23 January 2018
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma epidemiology and demographics |
|
FDA on Hepatocellular carcinoma epidemiology and demographics |
|
CDC on Hepatocellular carcinoma epidemiology and demographics |
|
Hepatocellular carcinoma epidemiology and demographics in the news |
|
Blogs on Hepatocellular carcinoma epidemiology and demographics |
|
Risk calculators and risk factors for Hepatocellular carcinoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2] Mohamad Alkateb, MBBCh [3]
Overview
Hepatocellular carcinoma is the 5th most common tumor worldwide. The epidemiology of hepatocellular carcinoma exhibits two main patterns, one in North America and Western Europe and the other in non-Western countries, such as those in Sub-Saharan Africa, Central Asia, Southeast Asia, and the Amazon basin. Men are affected more than women and it is more common between the 3rd and 5th decades of life. Hepatocellular carcinoma causes 662,000 deaths worldwide anually.
Epidemiology and Demographics
The epidemiology of hepatocellular carcinoma exhibits two main patterns, one in North America and Western Europe and the other in non-Western countries, such as those in Sub-Saharan Africa, Central Asia and Southeast Asia, and the Amazon basin. Although the incidence of hepatocellular carcinoma is increasing worldwide due to its association with viral infections; it still remains relatively uncommon in the United States and Western Europe. HCC is the fastest growing cause of cancer related deaths and the second most common cause of mortality among women.[1][2][3][4]
Incidence
In almost 90% of the cases Hepatocellular carcinoma patients have underlying liver cirrhosis.[5]
- The incidence of Hepatocellular carcinoma is described below:[6][7][5]
- In 1975-77, the incidence of Hepatocellular carcinoma in the United states was 1.4 per 100,000 which increased to 4.8 per 100,000 in 2005-2007.[8]
- In 2007, the incidence of Hepatocellular carcinoma was estimated to be over 20 cases per 100,000 persons in sub-Saharaa, Africa and Eastern Asia.
- In 2007, the incidence of Hepatocellular carcinoma was estimated to be 10-20 per 100,000 persons in Mediterranean countries such as Italy, Spain, and Greece.
- In 2007, the incidence of Hepatocellular carcinoma was estimated to be <5 per 100,000 persons in North and South America.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
Hepatocellular carcinoma is more common between the 3rd and 5th decades of life.
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
Males are more affected than females.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Hepatocellular carcinoma is generally a rare tumor in the West. Metastasis from other parts of the body is the main cause for developing hepatocellular carcinoma in the western countries. Due to the advancement in the health care system in the western countries, hepatocellular carcinoma is usually discovered at early stages in comparison to the developing countries such as Sub-Saharan Africa.
Developing Countries
In some parts of the world, such as Sub-Saharan Africa and Southeast Asia, hepatocellular carcinoma is the most common cancer. It affects men more than women and the age of onset is between late teens and early 30s. This variation is due to the different methods of hepatitis B transmission in different populations. For example, infection at or around birth predispose to earlier cancers than if people are infected later. The time to develop hepatocellular carcinoma after hepatitis B infection can varies from years to decades. The average survival time from the time of hepatocellular carcinoma diagnosis to death is about 5.9 months and about 3 months (median survival time) in Sub-Saharan Africa according to Manson's textbook of tropical diseases. Hepatocellular carcinoma is one of the deadliest cancers in China.
References
- ↑ Papadopoulos N, Argiana V, Deutsch M (2018). "Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management". Ann Gastroenterol. 31 (1): 35–41. doi:10.20524/aog.2017.0204. PMID 29333065.
- ↑ Didi-Kouko Coulibaly, Judith; Yeboua, Mireille; Kouassi Mbengue, Alphonsine; Kouadio, Emile Allah; Anzouan-Kacou Kissi, Henriette; Binan, Allah Yves-Omer; Lohoues Kouacou, Marie-Jeanne; Attia, Alain; N’Drin, Dominique Yao; Toutou, Toussaint; Adoubi, Innocent; Pineau, Pascal (2017). "Evolution of hepatocellular carcinoma epidemiology in Côte d'Ivoire". Bulletin du Cancer. 104 (11): 937–945. doi:10.1016/j.bulcan.2017.09.010. ISSN 0007-4551.
- ↑ "Cancer". World Health Organization. February 2006. Retrieved 2007-05-24.
- ↑ Budny A, Kozłowski P, Kamińska M, Jankiewicz M, Kolak A, Budny B, Budny W, Niemunis-Sawicka J, Szczypiór G, Kurniawka B, Burdan F (2017). "[Epidemiology and risk factors of hepatocellular carcinoma]". Pol. Merkur. Lekarski (in Polish). 43 (255): 133–139. PMID 28987047.
- ↑ 5.0 5.1 Colombo, Massimo; de Franchis, Roberto; Del Ninno, Ersilio; Sangiovanni, Angelo; De Fazio, Cristina; Tommasini, Maurizio; Donato, M. Francesca; Piva, Anna; Di Carlo, Valerio; Dioguardi, Nicola (1991). "Hepatocellular Carcinoma in Italian Patients with Cirrhosis". New England Journal of Medicine. 325 (10): 675–680. doi:10.1056/NEJM199109053251002. ISSN 0028-4793.
- ↑ Mittal S, El-Serag HB (2013). "Epidemiology of hepatocellular carcinoma: consider the population". J. Clin. Gastroenterol. 47 Suppl: S2–6. doi:10.1097/MCG.0b013e3182872f29. PMC 3683119. PMID 23632345.
- ↑ El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J (2007). "Epidemiology of hepatocellular carcinoma in Hispanics in the United States". Arch. Intern. Med. 167 (18): 1983–9. doi:10.1001/archinte.167.18.1983. PMID 17923599.
- ↑ Davila JA, El-Serag HB. The Rising Incidence of Hepatocellular Carcinoma in the United States: an Update. Gastroenterology. 2012;142(suppl 1):S914–S914.